# US 2011/0236951 A1 · Biocomposite materials and methods for making the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0236951 A1
- Document ID: US20110236951A1
- Status: Published application
- Kind: A1
- Application number: 11/983,516
- Filed: 2007-11-09
- Published: 2011-09-29
- Earliest claimed: 2002-12-20
- Assignees: Battelle Memorial Institute
- Inventors: Jay W. Grate; Jungbae Kim
- Web page: https://patentgrep.com/patent/US20110236951A1

## CPC

- C12N 11/14: Enzymes or microbial cells immobilised on or in an inorganic carrier
- C12N 11/06: attached to the carrier via a bridging agent
- C12N 11/087: Acrylic polymers
- C12N 11/089: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A particle (and a composition that includes a plurality of the particles) that includes at least one polypeptide molecule and at least one polymer covalently bound to the polypeptide molecule so as to form a polymer shell substantially encompassing the polypeptide molecule, wherein the particle does not define a dimension greater than about 1 μm. One example for making the particle includes modifying the polypeptide molecule to provide α, β-ethylenically unsaturated terminal functional groups, mixing the modified polypeptide molecule with a silicon-containing polymerizable compound, and subjecting the resulting mixture to conditions sufficient for polymerizing the polymerizable compound to form the particle.

## Claims

### Claim 1

A method for making a biocomposite material, comprising:
modifying a polypeptide to provide α, β-ethylenically unsaturated functional terminal groups;
mixing the modified polypeptide with a polymerizable compound that includes (i) a functional group reactive with the α, β-ethylenically unsaturated functional terminal group of the modified polypeptide, and (ii) a silicon-containing functional group;
subjecting the resulting mixture to conditions sufficient for forming a product that includes biocomposite particles that comprise the polypeptide and a polymer produced from the polymerizable compound; and
isolating a composition from the product, wherein substantially all of the biocomposite particles in the isolated composition each individually do not define a dimension greater than about 1 μm.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the polypeptide comprises an enzyme.

### Claim 3 (depends on 1)

The method according to claim 1, wherein isolating the composition comprises passing the product through a filter that defines a maximum pore size of 1 μm.

### Claim 4 (depends on 1)

The method according to claim 1, wherein substantially all of the biocomposite particles each individually do not define a dimension greater than about 200 nm, and the isolating of the composition comprises passing the product through a filter that defines a maximum pore size of 200 nm.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the α, β-ethylenically unsaturated functional terminal groups comprise vinyl groups, and the polymerizable compound comprises a carbon-unsaturated silane compound.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the subjecting of the resulting mixture to conditions sufficient for forming a product comprises free radical polymerizing the resulting mixture to produce an intermediate, and then hydrolyzing and condensing the intermediate to produce the product.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the hydrolyzing and condensing of the intermediate occurs simultaneously with the isolating of the composition from the product.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the hydrolyzing and condensing of the intermediate comprises:
providing the intermediate in an organic solvent phase;
mixing the organic solvent phase containing the intermediate with an aqueous buffer solution; and
extracting the product into the aqueous buffer solution.

### Claim 9 (depends on 8)

The method according to claim 8, further comprising passing the extracted aqueous buffer solution through a filter that defines a maximum pore size of 1 μm.

### Claim 10 (depends on 1)

The method according to claim 1, further comprising passing the modified polypeptide through a filter that defines a maximum pore size of 1 μm, and mixing the modified polypeptide particles in the filtrate with the polymerizable compound.

### Claim 11 (depends on 1)

The method according to claim 1, wherein a separate crosslinking agent is not added during the method.

### Claim 12 (depends on 1)

The method according to claim 1, wherein substantially all of the biocomposite particles contain a single polypeptide molecule.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the method results in a yield of biocomposite particles of about 35% to about 95%, based on the bioactivity of the polypeptide in the biocomposite particle divided by the initial bioactivity of the free polypeptide prior to synthesis of the biocomposite particle.

### Claim 14 (depends on 1)

The method according to claim 1, further comprising linking a first modified polypeptide molecule with a second modified polypeptide molecule, wherein the first modified polypeptide molecule and the second modified polypeptide molecule have different polypeptide structures.

### Claim 15

A method for making a biocomposite material, comprising:
modifying a protein to provide vinyl-containing functional terminal groups;
reacting the modified protein with at least one (meth)acryloxy-containing organosilane to produce a protein/silicon polymer intermediate; and
subjecting the protein/silicon polymer intermediate to conditions sufficient for producing a protein/polyorganosiloxane biocomposite.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the protein comprises an enzyme.

### Claim 17

A method for making a biocomposite particle, comprising
contacting at least one polypeptide molecule with at least one silane compound under conditions sufficient for bonding a functional group of the silane compound directly to a free amino, carboxyl, or sulfide group of the polypeptide molecule to form an intermediate product; and
subjecting the intermediate product to conditions sufficient for hydrolyzing and condensing the bound silane compound to form a polypeptide/polymer nanoparticle comprising a silicon-containing polymer shell bound to the polypeptide molecule.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the functional group of the silane compound comprises a succinyl group, an amino group, an epoxy group, or an isocyanato group.

### Claim 19

A method for making a biocomposite nanoparticle, comprising:
contacting at least one polypeptide molecule with at least one polyethylene glycol under conditions sufficient for forming an intermediate product that includes a covalent bond between the polypeptide molecule and a first functional group of the polyethylene glycol, wherein the polyethylene glycol includes a second functional group comprising a silyl group, a substituted silyl group, an amino, a carboxyl group, or a hydroxyl group; and
subjecting the intermediate product to conditions sufficient for forming a nanoparticle that includes a polymer shell derived from the polyethylene glycol such that the polymer shell is bound to the polypeptide molecule.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the second functional group of the polyethylene glycol comprises a silyl group or a substituted silyl group, and subjecting the intermediate product to conditions sufficient for forming a nanoparticle comprises hydrolyzing and condensing the silyl group or substituted silyl group.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the first functional group of the polyethylene glycol comprises an amino, a carboxyl group, a hydroxy group, a thiol group, or an acryl group.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the second functional group of the polyethylene glycol comprises an amino, a carboxyl group, or a hydroxyl group, and subjecting the intermediate product to conditions sufficient for forming a nanoparticle comprises reacting the intermediate product with at least one crosslinker selected from a dialdehyde, an isocyanate, a carbodiimide, polyethyleneimine, glycine, or lysine.

### Claim 23

A method for making a polypeptide/polymer nanoparticle, comprising:
modifying at least one polypeptide molecule to provide α, β-ethylenically unsaturated functional terminal groups;
mixing the modified polypeptide molecule with at least one polymerizable compound selected from acrylic acid or a (meth)acrylate;
subjecting the resulting mixture to conditions sufficient for forming a product that includes biocomposite particles that comprise the polypeptide and a polymer produced from the polymerizable compound; and
isolating a composition from the product, wherein substantially all of the biocomposite particles in the isolated composition each individually do not define a dimension greater than about 1 μm.
